# Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)

> **NCT05549284** · PHASE2 · RECRUITING · sponsor: **Affiliated Hospital to Academy of Military Medical Sciences** · enrollment: 36 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Orelabrutinib,Rituximab and Methotrexate

## Key facts

- **NCT ID:** NCT05549284
- **Lead sponsor:** Affiliated Hospital to Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2023-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549284, "Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05549284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*